Insulet price target raised to $310 from $300 at BTIG
BTIG raised the firm’s price target on Insulet (PODD) to $310 from $300 and keeps a Buy rating on the shares after its Q4 earnings beat. The ...
Yahoo Finance9d
BTIG downgrades General Dynamics on Gulfstream supply chain, certification
Investing.com -- BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025. The brokerage ...
Business Wire18d
BTIG to Host Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference on February 11 - 12, 2025
NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...
iRhythm price target raised to $135 from $120 at BTIG
BTIG analyst Marie Thibault raised the firm’s price target on iRhythm (IRTC) to $135 from $120 and keeps a Buy rating on the shares after its ...
Yahoo Finance1mon
Evolent Health price target lowered to $20 from $29 at BTIG
BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher ...
Nasdaq2mon
BTIG Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation
As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...